We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Type of COVID-19 Test Offers Advantages over Lateral Flow Tests

By LabMedica International staff writers
Posted on 14 Apr 2022

Rapid antigen tests can quickly and conveniently tell a person that they are positive for Covid-19. More...

However, because the antibody-based tests aren’t very sensitive, they can fail to detect early infections with low viral loads. Now, a team of researchers has developed a rapid test that relies on molecularly imprinted polymer nanoparticles, rather than antibodies, for detection.

The gold standard for COVID-19 diagnosis remains the reverse transcription-polymerase chain reaction (RT-PCR). Although this test is highly sensitive and specific, it takes 1-2 days to get a result, is expensive and requires special lab equipment and trained personnel. In contrast, rapid antigen tests are fast (15-30 minutes), and people can take them at home with no training, but they lack sensitivity, sometimes resulting in false negatives. Also, the tests use antibodies against SARS-CoV-2 for detection, which can’t withstand wide ranges of temperature and pH. The research team at Newcastle University (Newcastle, Tyne and Wear, UK) wanted to make a low-cost, rapid, robust and highly sensitive COVID-19 test that uses molecularly imprinted polymer nanoparticles (nanoMIPs) instead of antibodies.

To make nanoMIPs, the researchers began by attaching a peptide from the SARS-CoV-2 spike protein to a solid support. Then, they added nanoparticle building blocks and polymerized them around the peptide, creating nanoparticles with a binding site specific for the coronavirus spike protein. They isolated the nanoparticles that bound most strongly to the peptide and attached them to a screen-printed electrode. After showing that the nanoMIPs could bind SARS-CoV-2, they added the electrode to a small 3D-printed device that measured changes in thermal resistance that occurred upon binding.

When the team added samples from seven patient nasopharyngeal swabs to the device, the liquid flowed over the electrode, and the researchers detected a change in thermal resistance for samples that had previously tested positive for COVID-19 by RT-PCR. The test required only 15 minutes, and preliminary results indicated that it could detect a 6,000-times lower amount of SARS-CoV-2 than a commercial rapid antigen test. Unlike antibodies, the nanoMIPs withstood warm temperatures - which could give the test a longer shelf life in hot climates - and acidic pH - which might make it useful for monitoring SARS-CoV-2 in wastewater. However, to prove that the test has a lower false negative rate than existing rapid antigen tests, it must be tested on many more patient samples, according to the researchers.

“We develop a new type of COVID-19 test which has many advantages over current lateral flow tests. For example, lateral flow tests use biological antibodies to trap and detect the Covid-19 virus, whereas we use a synthetic alternative known as polymer antibodies. This allows for a test which is as fast - 15 mins, and cheap as a lateral flow test but can detect 6000-times smaller amounts of the COVID-19 virus,” said Dr. Marloes Peeters, Senior Lecturer at Newcastle University’s School of Engineering. “Consequently, this will improve test accuracy, particularly for asymptomatic or pre-symptomatic individuals. Moreover, synthetic antibodies are very robust which means the tests have a longer shelf-life, can be used in hot climates with no issues and will not produce false-positive results in acidic media, such as soft drinks.”

“In the future, we hope to further validate our polymer antibody by testing more patient samples, including saliva samples and samples from the omicron variant. Additionally, the polymer antibodies can be easily adapted for any new COVID-19 variants or other emerging pathogens,” added Dr. Peeters.

Related Links:
Newcastle University 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.